

Aktuelle Publikationen von Mitarbeitern oder unter Beteiligung von Mitarbeitern der Klinik und Poliklinik für Psychiatrie und Psychotherapie im Jahr 2000

Articles, Editorial Material, Letters, News Items, Notes und Reviews

Aschhoff S, Schroff KC, **Wildenauer DB**, Richter E. Nicotine consumption of several mouse strains using a two bottle choice paradigm.
J Exp Anim Sci. 2000;40(4): 171-7 (Impact(2004)=0.105)

Bagli M, Papassotiropoulos A, Jessen F, Rao ML, Maier W, Heun R. Gene-gene interaction between interleukin-6 and alpha2-macroglobulin influences the risk for Alzheimer's disease.
Ann Neurol. 2000;47(1): 138-9 (Impact(2004)=8.097)

Bagli M, Papassotiropoulos A, Jessen F, Schmitz S, Rao ML, Maier W, Heun R. Identical distribution of the alpha 2-macroglobulin pentanucleotide deletion in subjects with Alzheimer disease and controls in a German population.
Am J Med Genet. 2000;96(6): 775-7 (Impact(2004)=3.659)

Bagli M, Papassotiropoulos A, Knapp M, Jessen F, Rao ML, Maier W, Heun R. Association between an interleukin-6 promoter and 3' flanking region haplotype and reduced Alzheimer's disease risk in a German population.
Neurosci Lett. 2000;283(2): 109-12 (Impact(2004)=2.019)

Bayer TA, Schramm M, Feldmann N, Knable MB, Falkai P. Antidepressant drug exposure is associated with mRNA levels of tyrosine receptor kinase B in major depressive disorder.
Prog Neuropsychopharmacol Biol Psychiatry. 2000;24(6): 881-8 (Impact(2004)=2.149)

Block W, **Bayer TA, Tepest R, Träber F, Rietschel M, Müller DJ, Schulze TG, Honer WG, Maier W, Schild HH, Falkai P.** Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study.
Neurosci Lett. 2000;289(2): 147-51 (Impact(2004)=2.019)

Burgmer M, **Jessen F, Freyberger HJ.** Polythetic diagnostic approach to the borderline personality disorder. The valency of the single criterion in the concept of professional therapists.
Psychopathology. 2000;33(3): 119-24 (Impact(2004)=0.757)

Cichon S, Nöthen MM, **Rietschel M**, Propping P. Pharmacogenetics of schizophrenia.
Am J Med Genet. 2000;97(1): 98-106 (Impact(2004)=3.659)

Deckert J, Meyer J, Catalano M, Bosi M, Sand P, DiBella D, Ortega G, Stöber G, **Franke P**, Nöthen MM, Fritze J, **Maier W**, Beckmann H, Propping P, Bellodi L, Lesch KP. Novel 5'-regulatory region polymorphisms of the 5-HT_{2C} receptor gene: association study with panic disorder.
Int J Neuropsychopharmacol. 2000;3(4): 321-5 (Impact(2004)=4.128)

DeLisi LE, Craddock NJ, Detera-Wadleigh S, Foroud T, Gejman P, Kennedy JL, Lendon C, Macciardi F, McKeon P, Mynett-Johnson L, Nurnberger JI, Paterson A, **Schwab S**, Van Broeckhoven C, **Wildenauer D**, Crow TJ. Update on chromosomal locations for psychiatric disorders: report of the interim meeting of chromosome workshop chairpersons from the VIIth World Congress of Psychiatric Genetics, Monterey, California, October 14-18, 1999.
Am J Med Genet. 2000;96(3): 434-49 (Impact(2004)=3.659)

Elger G, Hoppe C, **Falkai P**, Rush AJ, Elger CE. Vagus nerve stimulation is associated with mood improvements in epilepsy patients.
Epilepsy Res. 2000;42(2-3): 203-10 (Impact(2004)=2.897)

Falkai P, Schneider-Axmann T, Honer WG. Entorhinal cortex pre-alpha cell clusters in schizophrenia: quantitative evidence of a developmental abnormality.
Biol Psychiatry. 2000;47(11): 937-43 (Impact(2004)=6.159)

Falkai P, Vogeley K. Die Chancen neuer atypischer Substanzen.
Fortschr Neurol Psychiatr. 2000;68 Suppl 1: S32-7 (Impact(2004)=0.752)

Finckh U, von der Kammer H, Velden J, Michel T, Andresen B, Deng A, Zhang J, Müller-Thomsen T, Zuchowski K, Menzer G, Mann U, **Papassotiropoulos A, Heun R,** Zurdel J, Holst F, Benussi L, Stoppe G, Reiss J, Miserez AR, Staehelin HB, Rebeck GW, Hyman BT, Binetti G, Hock C, Growdon JH, Nitsch RM. Genetic association of a cystatin C gene polymorphism with late-onset Alzheimer disease.
Arch Neurol. 2000;57(11): 1579-83 (Impact(2004)=4.835)

Franke P, Nöthen MM, Wang T, Knapp M, **Lichtermann D,** Neidt H, Sander T, Propping P, **Maier W.** DRD4 exon III VNTR polymorphism-susceptibility factor for heroin dependence? Results of a case-control and a family-based association approach.
Mol Psychiatry. 2000;5(1): 101-4 (Impact(2004)=6.943)

Franke P, Wang T, Nöthen MM, Knapp M, Neith H, **Lichtermann D,** Zur Capellen KM, Sander T, Propping P, **Maier W.** Susceptibility for alcoholism: DRD4 exon III polymorphism: a case-control and a family-based association approach.
Addict Biol. 2000;5(3): 289-95 (Impact(2004)=1.224)

Gross G, Huber G. The long-term outcome of schizophrenic and related disorders. A critical review.
Neurol Psychiat Brain Res. 2000;8(3): 121-30 (Impact(2004)=0.162)

Gross G, Huber G. The relevance of Jaspersian-Schneiderian psychopathology for today's psychiatry.
Neurol Psychiat Brain Res. 2000;8(2): 53-68 (Impact(2004)=0.162)

Grünhage F, **Schulze TG, Müller DJ,** Lanczik M, Franzek E, Albus M, Borrmann-Hassenbach M, Knapp M, Cichon S, **Maier W, Rietschel M,** Propping P, Nöthen MM. Systematic screening for DNA sequence variation in the coding region of the human dopamine transporter gene (DAT1).
Mol Psychiatry. 2000;5(3): 275-82 (Impact(2004)=6.943)

Hahn H, Wojnowski L, Specht K, Kappler R, Calzada-Wack J, Potter D, **Zimmer A,** Müller U, Samson E, Quintanilla-Martinez L, **Zimmer A.** Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma.
J Biol Chem. 2000;275(37): 28341-4 (Impact(2004)=6.355)

Hale A, Azorin JM, Kasper S, **Maier W,** Syvalahti E, Van der Burght M, Sloth-Nielsen M, Wehnert A. Sertindole improves both the positive and negative symptoms of schizophrenia: Results of a phase III trial.
Int J Soc Psychiatry. 2000;4(1): 55-62 (Impact(2004)=0.893)

Hale A, Azorin JM, Kasper S, **Maier W,** Syvalahti E, Van der Burght M, Sloth-Nielsen M, Wehnert A. Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial.
Int J Soc Psychiatry. 2000;4(1): 47-54 (Impact(2004)=0.893)

Hardt J, Gerbershagen HU, **Franke P.** The symptom check-list, SCL-90-R: its use and characteristics in chronic pain patients.
Eur J Pain. 2000;4(2): 137-48 (Impact(2004)=1.811)

Held T, Weber T, **Krausz H, Ahle G,** Hager B, **Alfter D, Schulze T,** Knapp M, **Maier W, Rietschel M.** Klinische Charakteristika von Patienten mit tardiven Dyskinesien.
Fortschr Neurol Psychiatr. 2000;68(7): 321-31 (Impact(2004)=0.752)

Heun R, Jessen F, Klose U, Erb M, Granath D, Freymann N, Grodd W. Interindividual variation of cerebral activation during encoding and retrieval of words.
Eur Psychiatry. 2000;15(8): 470-9 (Impact(2004)=1.191)

Heun R, Jessen F, Klose U, Erb M, Granath DO, Grodd W. Response-related fMRI analysis during encoding and retrieval revealed differences in cerebral activation by retrieval success.
Psychiatry Res. 2000;99(3): 137-50 (Impact(2004)=1.989)

Heun R, Kockler M, Papassotiropoulos A. Distinction of early- and late-onset depression in the elderly by their lifetime symptomatology.
Int J Geriatr Psychiatry. 2000;15(12): 1138-42 (Impact(2004)=1.971)

Heun R, Papassotiropoulos A, Ptok U. Subthreshold depressive and anxiety disorders in the elderly.
Eur Psychiatry. 2000;15(3): 173-82 (Impact(2004)=1.191)

Holinski-Feder E, Reyniers E, Uhrig S, Golla A, Wauters J, Kroisel P, Bossuyt P, Rost I, Jedele K, Zierler H, **Schwab S, Wildenauer D,** Speicher MR, Willems PJ, Meitinger T, Kooy RF. Familial mental retardation syndrome ATR-16 due to an inherited cryptic subtelomeric translocation, t(3;16)(q29;p13.3).
Am J Hum Genet. 2000;66(1): 16-25 (Impact(2004)=12.34)

Hranilovic D, **Schwab SG,** Jernej B, Knapp M, Lerer B, Albus M, **Rietschel M,** Kanyas K, Borrmann M, **Lichtermann D, Maier W, Wildenauer DB.** Serotonin transporter gene and schizophrenia: evidence for association/linkage disequilibrium in families with affected siblings.
Mol Psychiatry. 2000;5(1): 91-5 (Impact(2004)=6.943)

Ishii K, Muelhauser F, Liebl U, Picard M, Kühl S, Penke B, **Bayer T,** Wiessler M, Hennerici M, Beyreuther K, Hartmann T, Fassbender K. Subacute NO generation induced by Alzheimer's beta-amyloid in the living brain: reversal by inhibition of the inducible NO synthase.
FASEB J. 2000;14(11): 1485-9 (Impact(2004)=6.82)

Jessen F, Block W, Träber F, Keller E, Flacke S, **Papassotiropoulos A,** Lamerichs R, **Heun R,** Schild HH. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD.
Neurology. 2000;55(5): 684-8 (Impact(2004)=5.973)

Jessen F, Heun R, Erb M, **Granath DO,** Klose U, **Papassotiropoulos A,** Grodd W. The concreteness effect: evidence for dual coding and context availability.
Brain Lang. 2000;74(1): 103-12 (Impact(2004)=1.614)

Kawasak Y, Vogeley K, Jung V, Tepest R, Hütte H, Schleicher A, **Falkai P.** Automated image analysis of disturbed cytoarchitecture in Brodmann area 10 in schizophrenia: a post-mortem study.
Prog Neuropsychopharmacol Biol Psychiatry. 2000;24(7): 1093-104 (Impact(2004)=2.149)

Kölsch H, Ludwig M, Lütjohann D, Prange W, **Rao ML.** 7alpha-Hydroperoxycholesterol causes CNS neuronal cell death.
Neurochem Int. 2000;36(6): 507-12 (Impact(2004)=3.211)

Krauss H, Marwinski K, Schulze T, Müller DJ, Held T, **Rietschel M, Maier W, Freyberger HJ.** Zur Reliabilität und Validität der deutschen Version der Prämorbiditen Anpassungsskala (PAS).
Nervenarzt. 2000;71(3): 188-94 (Impact(2004)=0.899)

Kremer I, **Rietschel M,** Dobrusin M, Mujahed M, Murad I, Blanaru M, Bannoura I, **Müller DJ, Schulze TG,** Reshef A, **Gathas S, Schwab S, Wildenauer D,** Bachner-Melman R, Belmaker RH, **Maier W,** Ebstein RP. No association between the dopamine D3 receptor 3'UTR polymorphism and schizophrenia in a family-based study of a Palestinian Arab population.
Am J Med Genet. 2000;96(6): 778-80 (Impact(2004)=3.659)

Kühn KU, Meyer K, Maier W. Flupenthixol--ein partiell atypisches Neuroleptikum?
Fortschr Neurol Psychiatr. 2000;68 Suppl 1: S38-41 (Impact(2004)=0.752)

Levinson DF, Holmans P, Straub RE, Owen MJ, **Wildenauer DB**, Gejman PV, Pulver AE, Laurent C, Kendler KS, Walsh D, Norton N, Williams NM, **Schwab SG**, Lerer B, Mowry BJ, Sanders AR, Antonarakis SE, Blouin JL, DeLeuze JF, Mallet J. Multicenter linkage study of schizophrenia candidate regions on chromosomes 5q, 6q, 10p, and 13q: schizophrenia linkage collaborative group III. *Am J Hum Genet.* 2000;67(3): 652-63 (Impact(2004)=12.34)

Lichtermann D, Franke P, Maier W, Rao ML. Pharmacogenomics and addiction to opiates. *Eur J Pharmacol.* 2000;410(2-3): 269-79 (Impact(2004)=2.432)

Lichtermann D, Hranilovic D, Trixler M, Franke P, Jernej B, Delmo CD, Knapp M, Schwab SG, Maier W, Wildenauer DB. Support for allelic association of a polymorphic site in the promoter region of the serotonin transporter gene with risk for alcohol dependence. *Am J Psychiatry.* 2000;157(12): 2045-7 (Impact(2004)=7.614)

Lichtermann D, Karbe E, Maier W. The genetic epidemiology of schizophrenia and of schizophrenia spectrum disorders. *Eur Arch Psychiatry Clin Neurosci.* 2000;250(6): 304-10 (Impact(2004)=1.87)

Lucht MJ, Kleinschmidt R, **Maier W, Rietschel M.** Agranulocytosis during treatment with mianserin and venlafaxine. *J Clin Psychopharmacol.* 2000;20(4): 490-1 (Impact(2004)=4.419)

Lütjohann D, **Papassotiropoulos A**, Björkhem I, Locatelli S, **Bagli M**, Oehring RD, Schlegel U, **Jessen F, Rao ML**, von Bergmann K, **Heun R.** Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. *J Lipid Res.* 2000;41(2): 195-8 (Impact(2004)=4.159)

Maier W, Gänsicke M, Freyberger HJ, Linz M, Heun R, Lecrubier Y. Generalized anxiety disorder (ICD-10) in primary care from a cross-cultural perspective: a valid diagnostic entity? *Acta Psychiatr Scand.* 2000;101(1): 29-36 (Impact(2004)=2.288)

Maier W, Linz M, Hawellek B. Genetik der Persönlichkeitsstörungen. *Persönlichkeitsstörungen, Theorie und Therapie.* 2000;4: 182-92

Maier W, Schwab S, Rietschel M. The genetics of schizophrenia. *Curr Opin Psychiatry.* 2000;13(1): 3-9 (Impact(2004)=0.893)

Majores M, Bagli M, Papassotiropoulos A, Schwab SG, Jessen F, Rao ML, Maier W, Heun R. Allelic association between the D10S1423 marker and Alzheimer's disease in a German population. *Neurosci Lett.* 2000;289(3): 224-6 (Impact(2004)=2.019)

Mass R, Wolf K, **Wagner M**, Haasen C. Differential sustained attention/vigilance changes over time in schizophrenics and controls during a degraded stimulus Continuous Performance Test. *Eur Arch Psychiatry Clin Neurosci.* 2000;250(1): 24-30 (Impact(2004)=1.87)

Oades RD, **Rao ML**, Bender S, Sartory G, Müller BW. Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy. *Behav Pharmacol.* 2000;11(3-4): 317-30 (Impact(2004)=2.301)

Papassotiropoulos A, Bagli M, Becker K, Jessen F, Maier W, Rao ML, Ludwig M, Heun R. No association between an intronic biallelic polymorphism of the FE65 gene and Alzheimer's disease. *Int J Mol Med.* 2000;6(5): 587-9 (Impact(2004)=3.19)

Papassotiropoulos A, Bagli M, Jessen F, Frahnert C, Rao ML, Maier W, Heun R. Confirmation of the association between bleomycin hydrolase genotype and Alzheimer's disease. *Mol Psychiatry.* 2000;5(2): 213-5 (Impact(2004)=6.943)

Papassotiropoulos A, Bagli M, Jessen F, Maier W, Förstl H, Kurz A, Heun R. Interaction of two genes possibly involved in the regulation of the amyloid precursor protein (APP) processing. *Mol Psychiatry*. 2000;5(3): 240-1 (Impact(2004)=6.943)

Papassotiropoulos A, Bagli M, Kurz A, Kornhuber J, Förstl H, Maier W, Pauls J, Lautenschlager N, Heun R. A genetic variation of cathepsin D is a major risk factor for Alzheimer's disease. *Ann Neurol*. 2000;47(3): 399-403 (Impact(2004)=8.097)

Papassotiropoulos A, Lütjohann D, Bagli M, Locatelli S, Jessen F, Rao ML, Maier W, Björkhem I, von Bergmann K, Heun R. Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. *Neuroreport*. 2000;11(9): 1959-62 (Impact(2004)=2.351)

Ptok U, Papassotiropoulos A, Maier W, Heun R. Advanced parental age: a risk factor for Alzheimer's disease or depression in the elderly? *Int Psychogeriatr*. 2000;12(4): 445-51 (Impact(2004)=0.91)

Rietschel M, Krauss H, Müller DJ, Schulze TG, Knapp M, Marwinski K, Maroldt AO, Paus S, Grünhage F, Propping P, Maier W, Held T, Nöthen MM. Dopamine D3 receptor variant and tardive dyskinesia. *Eur Arch Psychiatry Clin Neurosci*. 2000;250(1): 31-5 (Impact(2004)=1.87)

Rietschel M, Schorr A, Albus M, Franzek E, Kreiner R, Held T, Knapp M, Müller DJ, Schulze TG, Propping P, Maier W, Nöthen MM. Association study of the tryptophan hydroxylase gene and bipolar affective disorder using family-based internal controls. *Am J Med Genet*. 2000;96(3): 310-1 (Impact(2004)=3.659)

Sand PG, Godau C, Riederer P, Peters C, **Franke P, Nöthen MM, Stöber G, Fritze J, Maier W, Propping P, Lesch KP, Riess O, Sander T, Beckmann H, Deckert J.** Exonic variants of the GABA(B) receptor gene and panic disorder. *Psychiatr Genet*. 2000;10(4): 191-4 (Impact(2004)=2.162)

Sand P, Lesch KP, Catalano M, Bosi M, Syagailo YV, Okladnova O, Di Bella D, Maffei P, Heils A, Friess F, Politi E, Nöthen MM, **Franke P, Stöber G, Fritze J, Maier W, Propping P, Beckmann H, Bellodi L, Riederer P, Deckert J.** Polymorphic MAO-A and 5-HT-transporter genes: analysis of interactions in panic disorder. *World J Biol Psychiatry*. 2000;1(3): 147-50

Schmidt S, **Papassotiropoulos A, Bagli M, Harzheim M, Heun R, Klockgether T.** No association of serum levels of interleukin-6 and its soluble receptor components with a genetic variation in the 3'flanking region of the interleukin-6 gene in patients with multiple sclerosis. *Neurosci Lett*. 2000;294(3): 139-42 (Impact(2004)=2.019)

Schulze TG, Müller DJ, Krauss H, Scherk H, Ohlraun S, Syagailo YV, Windemuth C, Neidt H, Grässle M, Papassotiropoulos A, Heun R, Nöthen MM, Maier W, Lesch KP, Rietschel M. Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder. *Am J Med Genet*. 2000;96(6): 801-3 (Impact(2004)=3.659)

Schumacher J, **Schulze TG, Wienker TF, Rietschel M, Nöthen MM.** Pharmacogenetics of the clozapine response. *Lancet*. 2000;356(9228): 506-7 (Impact(2004)=21.713)

Schwab SG, Hallmayer J, Albus M, Lerer B, Eckstein GN, Borrmann M, Segman RH, Hanses C, Freymann J, Yakir A, Trixler M, Falkai P, Rietschel M, Maier W, Wildenauer DB. A genome-wide autosomal screen for schizophrenia susceptibility loci in 71 families with affected siblings: support for loci on chromosome 10p and 6. *Mol Psychiatry*. 2000;5(6): 638-49 (Impact(2004)=6.943)

Thier M, Roeb E, Breuer B, **Bayer TA**, Halfter H, Weis J. Expression of matrix metalloproteinase-2 in glial and neuronal tumor cell lines: inverse correlation with proliferation rate. *Cancer Lett.* 2000;149(1-2): 163-70 (Impact(2004)=2.938)

Valverde O, Maldonado R, Valjent E, **Zimmer AM**, **Zimmer A**. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. *J Neurosci.* 2000;20(24): 9284-9 (Impact(2004)=7.907)

Vogele K, **Schneider-Axmann T**, **Pfeiffer U**, **Tepest R**, **Bayer TA**, **Bogerts B**, **Honer WG**, **Falkai P**. Disturbed gyrification of the prefrontal region in male schizophrenic patients: A morphometric postmortem study. *Am J Psychiatry.* 2000;157(1): 34-9 (Impact(2004)=7.614)

Vogt IR, Shimron-Abarbanell D, Neidt H, Erdmann J, Cichon S, **Schulze TG**, **Müller DJ**, **Maier W**, Albus M, Borrmann-Hassenbach M, Knapp M, **Rietschel M**, Propping P, Nöthen MM. Investigation of the human serotonin 6 [5-HT6] receptor gene in bipolar affective disorder and schizophrenia. *Am J Med Genet.* 2000;96(2): 217-21 (Impact(2004)=3.659)

Weggen S, **Bayer TA**, von Deimling A, Reifenberger G, von Schweinitz D, Wiestler OD, Pietsch T. Low frequency of SV40, JC and BK polyomavirus sequences in human medulloblastomas, meningiomas and ependymomas. *Brain Pathol.* 2000;10(1): 85-92 (Impact(2004)=3.958)

Weigmann H, Härtter S, **Bagli M**, Hiemke C. Steady state concentrations of clomipramine and its major metabolite desmethylclomipramine in rat brain and serum after oral administration of clomipramine. *Eur Neuropsychopharmacol.* 2000;10(5): 401-5 (Impact(2004)=3.545)

Wirths O, **Weickert S**, Majtenyi K, Havas L, Kahle PJ, Okochi M, Haass C, Multhaup G, Beyreuther K, **Bayer TA**. Lewy body variant of Alzheimer's disease: alpha-synuclein in dystrophic neurites of A beta plaques. *Neuroreport.* 2000;11(17): 3737-41 (Impact(2004)=2.351)

Zhao H, Zhang S, Merikangas KR, Tixler M, **Wildenauer DB**, Sun F, Kidd KK. Transmission/disequilibrium tests using multiple tightly linked markers. *Am J Hum Genet.* 2000;67(4): 936-46 (Impact(2004)=12.34)

Bücher und Buchbeiträge

Maier W (Hrsg.) (2000) Neuere Entwicklungen in der Diagnostik und Therapie der Schizophrenie. Fortschritte der Neurologie, Psychiatrie 68 (Sonderheft 1).

Maier W, Engel RR, Möller H-J (Hrsg.) (2000) Methodik von Verlaufs- und Therapiestudien in Psychiatrie und Psychotherapie. Hogrefe, Göttingen.

Maier W, **Franke P** (2000) Genetik von substanzgebundenen Abhängigkeitserkrankungen. In: Stimmer F (Hrsg.) Suchtlexikon. Oldenbourg, München (270-275).

Maier W, **Schwab S**, **Rietschel M** (2000) Genetik affektiver Störungen. In: Helmchen H, Henn F, Lauter H, Sartorius N (Hrsg.) Psychiatrie der Gegenwart, Bd. 5: Schizophrene und affektive Störungen. Springer, Berlin (373-407).

Maier W, **Schwab S**, **Rietschel M** (2000) Genetik funktioneller psychischer Störungen. In: Möller H-J, Laux G, Kapfhammer H-P (Hrsg.) Psychiatrie und Psychotherapie. Springer, Berlin (69-101).